Stockscreener 앱 받기
987.05
0.18%
-1.82
시간 외 거래:
984.50
-2.55
-0.26%
전일 마감가:
$988.87
열려 있는:
$991.35
하루 거래량:
3.74M
Relative Volume:
1.15
시가총액:
$880.19B
수익:
$72.25B
순이익/손실:
$25.28B
주가수익비율:
35.53
EPS:
27.781
순현금흐름:
$10.37B
1주 성능:
+15.96%
1개월 성능:
+6.47%
6개월 성능:
+5.29%
1년 성능:
+27.34%
1일 변동 폭
$983.50
$996.49
1주일 범위
$896.80
$996.49
52주 변동 폭
$623.78
$1,133.95
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
987.05 | 881.82B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.62 | 542.95B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
205.03 | 364.56B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.92 | 281.08B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
148.36 | 277.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-16 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 재확인 | BofA Securities | Buy |
| 2025-12-15 | 재확인 | Goldman | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-10 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Lilly looks to sell about $8B of debt to fund acquisitions - Indianapolis Business Journal
Quarterly Sales Reach $8.7 Billion, Eli Lilly’s Mounjaro Becomes New Blockbuster Drug King - NAI500
Eli Lilly's Mounjaro overtakes Merck's Keytruda as world's top-selling drug - Business Standard
Change of leadership in the pharmaceutical world! Eli Lilly and Co's Mounjaro surpasses Merck & Co's Keytruda to become the world's best-selling drug. - 富途牛牛
Change of the top-selling drug! Eli Lilly and Co's Mounjaro surpasses Merck & Co's Keytruda to become the world's best-selling drug. - 富途牛牛
Lilly unveils new genetic medicine facility in Lebanon LEAP District and $4.5 billion investment - WFYI
Lilly’s Mounjaro overtakes Keytruda as world’s top-selling drug - The Boston Globe
Eli Lilly: Files for Eight Part Notes Offerin - Moomoo
Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence - Yahoo Finance
Top Research Reports for Eli Lilly, Western Digital & Vertiv - Yahoo Finance Singapore
[144] ELI LILLY & Co SEC Filing - Stock Titan
Eli Lilly Kicks Off High-Grade Bond Sale in Push to Fund Deals - Bloomberg.com
Lilly’s Mounjaro Overtakes ‘King Keytruda’ as World’s Top-Selling Drug - Bloomberg.com
Meet the minds behind CrossBridge Bio, Eli Lilly's $300M Houston buy - The Business Journals
Eli Lilly Opens First Dedicated Genetic Medicine Facility - Pharmaceutical Commerce
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits? - Yahoo Finance Singapore
Lilly Invests $4.5 Billion to Expand Indiana Manufacturing Sites - Bloomberg.com
Lilly pours $4.5B more into LEAP, as first facility opens in Lebanon - AOL.com
Eli Lilly commits additional $4.5B to Indiana manufacturing sites - WTHR
Lilly to invest additional $4.5 billion across Indiana manufacturing sites - WRTV
Lilly commits additional $4.5 billion in Indiana manufacturing sites - Reuters
Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions - Moomoo
Eli Lilly and Company announces additional $4.5 billion investment in 2 Lebanon sites - fox59.com
Eli Lilly (LLY) Stock: Lilly Is Building the Largest Drug Plant in U.S. History - CoinCentral
Lilly commits $4.5 billion to Indiana manufacturing expansion By Investing.com - Investing.com Canada
Lilly announces additional $4.5B investment at LEAP District manufacturing site - Inside INdiana Business
Lilly invests $4.5 billion to expand Indiana manufacturing sites - MSN
Novo Nordisk weight-loss pill powers profit beat in race to catch Eli Lilly - Reuters
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility - investor.lilly.com
Eli Lilly (LLY) files prospectus for multi‑series floating and fixed notes - Stock Titan
Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook - Benzinga
Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight - TechStock²
Novo Nordisk’s weight loss pill helps narrow gap with rival Lilly - whbl.com
Signal: Eli Lilly Stock Remains a "Buy" After Earnings - Schaeffer's Investment Research
Foundayo Liver Safety Questions Test Eli Lilly GLP-1 Growth Story - simplywall.st
Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show - 24/7 Wall St.
Are analysts too quick to gloss over Lilly’s liver case? - statnews.com
Eli Lilly Is Maintained at Overweight by Barclays - Moomoo
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,183 to $1,500 - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Icon (ICLR) - The Globe and Mail
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years - investor.lilly.com
Eli Lilly Stock (LLY) Opinions on Q1 Earnings and Foundayo Safety Report - Moomoo
3 Reasons It's Not Too Late to Buy Eli Lilly Stock - The Motley Fool
Eli Lilly and Co To Go Ex-Dividend On May 15th, 2026 With 1.73 USD Dividend Per Share - Moomoo
Is Eli Lilly stock heading for $1,000? - MSN
Eli Lilly Annual Meeting: Directors Win, Governance Changes Fail as Ricks Touts 45% Revenue Jump - Yahoo Finance
Is Eli Lilly Stock Heading for $1,000? - The Motley Fool
Eli Lilly (LLY) Faces Share Decline Amid Liver Failure Report Li - GuruFocus
Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125% - 24/7 Wall St.
Eli Lilly Recovers After Weight-Loss Patient Reports A Surprise Side Effect - Investor's Business Daily
Stock Quote & Chart | Eli Lilly and Company - investor.lilly.com
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
2.03%
자본화:
|
볼륨(24시간):